NCT03020901

Brief Summary

  1. 1.Primary study endpoint Security Effectiveness
  2. 2.Secondary study endpoint Extensive use of population characteristics Clinical drug characteristics appropriate crowd characteristics Adverse reactions susceptible population characteristics Reveal rare, new, unanticipated and long-term adverse drug reactions bacterial resistance Explore the advantages of teicoplanin in combination with other antimicrobial agents Explore the opportunistic use of teicoplanin for injection

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2017

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2017

Completed
5 days until next milestone

First Submitted

Initial submission to the registry

January 6, 2017

Completed
7 days until next milestone

First Posted

Study publicly available on registry

January 13, 2017

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2018

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2018

Completed
Last Updated

January 13, 2017

Status Verified

January 1, 2017

Enrollment Period

1.6 years

First QC Date

January 6, 2017

Last Update Submit

January 11, 2017

Conditions

Infectious Disease

Outcome Measures

Primary Outcomes (1)

  • Bacterial clearance rate

    1-21 days after injection

Interventions

Teicoplanin for InjectionDRUG

Use Teicoplanin for Injection

Also known as: Ta Ge Shi

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Prescription for teicoplanin in patients

You may qualify if:

  • Prescription for teicoplanin in patients

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Communicable Diseases

Interventions

TeicoplaninInjections

Condition Hierarchy (Ancestors)

InfectionsDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

LipoglycopeptidesGlycopeptidesGlycoconjugatesCarbohydratesPeptidesAmino Acids, Peptides, and ProteinsDrug Administration RoutesDrug TherapyTherapeutics

Central Study Contacts

Yingchun Xu, Doctor

CONTACT

13911303028xycpumch@139.com

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 6, 2017

First Posted

January 13, 2017

Study Start

January 1, 2017

Primary Completion

August 1, 2018

Study Completion

December 1, 2018

Last Updated

January 13, 2017

Record last verified: 2017-01